December 29, 2015

Mr. Bruce Broussard
Chief Executive Officer
Humana, Inc.
500 West Main Street
6th Floor – Humana Tower
Louisville, KY 40202


Dear Mr. Broussard:

Pursuant to 42 C.F.R. § 422.752(c)(1), § 422.760(b), § 423.752(c)(1), and § 423.760(b), the Centers for Medicare & Medicaid Services (CMS) is providing notice to Humana, Inc. (Humana), that CMS has made a determination to impose a civil money penalty (CMP) in the total amount of $3,100,900 on Medicare Advantage-Prescription Drug (MA-PD) and Prescription Drug Plan (PDP) Contract Numbers: H0028, H0108, H0336, H1019, H1036, H1291, H1406, H1418, H1468, H1510, H1716, H1906, H1951, H2012, H2029, H2486, H2649, H2944, H2949, H3480, H3533, H4007, H4141, H4145, H4461, H4510, H5216, H5415, H5525, H5619, H5970, H6609, H6622, H6859, H8145, H8908, H8953, R5826, S2874, S5552, and S5884.

CMS has determined that Humana failed to provide its enrollees with Medicare benefits in accordance with CMS requirements. An MA-PD’s and PDP’s central mission is to provide Medicare enrollees with medical services and prescription drug benefits within a framework of Medicare requirements that provide enrollees with a number of protections.

Summary of Noncompliance

CMS conducted an audit of Humana’s Medicare operations from April 20, 2015 through May 7, 2015. In a program audit report issued on November 3, 2015, CMS auditors reported that Humana failed to comply with Medicare requirements related to Part D formulary and benefit
administration and Part C and Part D organization/coverage determinations, appeals, and grievances in violation of 42 C.F.R. Part 422, Subpart M and 42 C.F.R. Part 423, Subparts C and M. Humana’s failures in these areas were systemic and resulted in enrollees experiencing inappropriate delays or denials in receiving covered benefits or increased out-of-pocket costs.

**Part D Formulary and Benefit Administration Relevant Requirements**

Medicare Part D Prescription Drug Program requirements apply to stand-alone Prescription Drug Plan sponsors and to Medicare Advantage sponsors that offer prescription drug benefits. Sponsors of these plans (Part D Sponsors) are required to enter into an agreement with CMS by which the sponsor agrees to comply with a number of requirements based upon statute, regulations, and program instructions.

*Formulary*

(42 C.F.R. §§ 423.120(b)(2)(iv) and 423.120(b)(4)-(6); Internet Only Manual (IOM) Pub.100-18 Medicare Prescription Drug Benefit Manual, Chapter 6, Section 30.3)

Each Part D sponsor maintains a drug formulary or list of prescription medications covered by the sponsor. A number of Medicare requirements govern how Part D sponsors create and manage their formularies. Each Part D sponsor is required to submit its formulary for review and approval by CMS on an annual basis. A Part D sponsor can change its formulary mid-year, but in order to do so must first obtain prior CMS approval, and then notify its enrollees of any changes, in addition to changes in cost-sharing amounts for formulary drugs. The CMS formulary review and approval process includes a review of the Part D sponsor’s proposed drug utilization management processes to adjudicate Medicare prescription drug claims (Part D claims).

*Utilization Management Techniques*


Prior authorization is a utilization management technique used by Part D sponsors (as well as commercial and other health insurers) that requires enrollees to obtain approval from the sponsor for coverage of certain prescriptions prior to being dispensed the medication. Part D enrollees can find out if prior authorization is required for a prescription by asking their physician or checking their plan’s formulary (which is available online). Prior authorization guidelines are determined on a drug-by-drug basis and may be based on Food and Drug Administration (FDA) and manufacturer guidelines, medical literature, safety, appropriate use, and benefit design.

Quantity limits are another utilization management technique used by Part D sponsors. A sponsor may place a quantity limit on a drug for a number of reasons. A quantity limit may be placed on a medication as a safety edit based on FDA maximum daily dose limits. Quantity limits may also be placed on a drug for dosage optimization, which helps to contain costs.
In addition, Part D sponsors (as well as commercial and other health insurers) use step therapy to ensure that when enrollees begin drug therapy for a medical condition, the first drug chosen is cost-effective and safe and other more costly or risky drugs are only prescribed if they prove to be clinically necessary. The goal of step therapy is to control costs and minimize clinical risks.

**Violations Related to Formulary & Benefit Administration**

CMS identified violations of Part D formulary and benefit administration requirements that resulted in Humana’s enrollees experiencing inappropriate denials of coverage at the point of sale. Humana’s violations include:

1. Failure to properly administer its CMS-approved formulary by applying unapproved quantity limits. As a result, enrollees experienced inappropriate denials of coverage at the point of sale and were delayed access to drugs, never received the drugs, or incurred increased out-of-pocket costs in order to receive the drugs. This is in violation of 42 C.F.R. § 423.120(b)(2); and IOM Pub. 100-18, Medicare Prescription Drug Benefit Manual, Chapter 6, Section 30.2, and Chapter 7, Section 60.6.

2. Failure to properly administer its CMS-approved formulary by applying unapproved prior authorization edits. As a result, enrollees experienced inappropriate denials of coverage at the point of sale and were delayed access to drugs, never received the drugs, or incurred increased out-of-pocket costs in order to receive the drugs. This is in violation of 42 C.F.R. § 423.120(b)(2); and IOM Pub. 100-18, Medicare Prescription Drug Benefit Manual, Chapter 6, Section 30.2.

**Part C and Part D Organization/Coverage Determination, Appeal, and Grievance Relevant Requirements**


Medicare enrollees have the right to contact their plan sponsor to express general dissatisfaction with the operations, activities, or behavior of the plan sponsor or to make a specific complaint about the denial of coverage for drugs or services to which the enrollee believes he or she is entitled. Sponsors are required to classify general complaints about services, benefits, or the sponsor’s operations or activities as grievances. Sponsors are required to classify complaints about coverage for drugs or services as organization determinations (Part C – medical services) or coverage determinations (Part D – drug benefits). It is critical for a sponsor to properly classify each complaint as a grievance or an organization/coverage determination or both. Improper classification of an organization or coverage determination denies an enrollee the applicable due process and appeal rights and may delay an enrollee’s access to medically necessary or life-sustaining services or drugs.

The enrollee, the enrollee’s representative, or the enrollee’s treating physician or prescriber may make a request for an organization determination or coverage determination. The first level of review is the organization determination or coverage determination, which is conducted by the
plan sponsor, and the point at which beneficiaries or their physicians submit justification for the benefit.

If the organization or coverage determination is adverse (not in favor of the beneficiary), the beneficiary has the right to file an appeal. The first level of the appeal – called a reconsideration (Part C) or redetermination (Part D) – is handled by the plan sponsor and must be conducted by a physician who was not involved in the organization determination or coverage determination decision. The second level of appeal is made to an independent review entity (IRE) contracted by CMS.

There are different decision making timeframes for the review of organization determinations, coverage determinations, and appeals. CMS has a beneficiary protection process in place that requires plans to forward coverage determinations and appeals to the IRE when the plan has missed the applicable adjudication timeframe.

Violations Related to Part C and Part D Organization/Coverage Determinations, Appeals and Grievances

CMS identified violations of Part C and Part D organization/coverage determination, appeal, and grievance requirements that resulted in Humana’s enrollees being inappropriately delayed or denied access to medical services and/or drugs. Humana’s violations include:

3. Failure to notify enrollees, or their prescribers, of decisions within 72 hours of receipt of expedited redetermination requests. As a result, enrollees were untimely notified of the outcome of their expedited redetermination requests and may have experienced delays in access to medications. This is in violation of 42 C.F.R. § 423.590(d); and IOM Pub, 100-18, Medicare Prescription Drug Benefit Manual, Chapter 18, Sections 70.9.3, 70.9.4, and 70.8.1.

4. Failure to demonstrate sufficient outreach to prescribers or enrollees to obtain additional information necessary to make appropriate clinical decisions. As a result, enrollees may have experienced inappropriate denials of coverage due to insufficient provider outreach. This is in violation of 42 C.F.R §§ 423.566(a), 423.578 and 423.586; and IOM Pub. 100-18, Medicare Prescription Drug Benefit Manual, Chapter 18, Sections 10.2, 30.2, 70.5, 70.7 and 70.8.

5. Inappropriately classified redeterminations as coverage determinations. As a result, enrollees were denied a second-level review and the appeal rights that are associated with an adverse decision at that level. This is in violation of 42 C.F.R. § 423.580; and IOM Pub. 100-18, Medicare Prescription Drug Benefit Manual, Chapter 18, Sections 10.2, 30.2, 70.5, 70.7 and 70.

6. Misclassified coverage determination or appeal requests as grievances and/or customer service inquiries. As a result, enrollees’ requests were not processed with the correct adjudicatory time requirements and appeal rights, which likely resulted in delays in receiving a coverage decision or the inability to appeal adverse decisions. This is in
violation of 42 C.F.R. § 423.564(b); and IOM Pub. 100-18, Medicare Prescription Drug Benefit Manual, Chapter 18, Sections 20.2.4.1, 20.2.4.2, and 30.4.

7. Failure to notify enrollees of decisions within 14 calendar days of receipt of standard pre-service organization determination requests. As a result, enrollees either did not receive any notification or were untimely notified of the outcome of their pre-service organization determination requests and may have experienced delays in receiving medical services. This is in violation of 42 C.F.R. § 422.568(b); and IOM Pub. 100-16, Medicare Managed Care Manual, Chapter 13, Section 40.1, Paragraph 1.

Basis for Civil Money Penalty

Pursuant to 42 C.F.R. § 422.752(c)(1), § 422.760(b), § 423.752(c)(1), and § 423.760(b), CMS has determined that Humana’s violations of Parts C and D requirements directly adversely affected (or had the substantial likelihood of adversely affecting) enrollees and warrants the imposition of a CMP. Humana failed substantially:

- To carry out the terms of its contract with CMS (42 C.F.R. § 422.510(a)(1) and 42 C.F.R. § 423.509(a)(1));
- To comply with the Part D service access requirements in § 423.120 (42 C.F.R. § 423.509(a)(4)(iv));
- To comply with the requirements in Subpart M relating to grievances and appeals (42 C.F.R. § 422.510(a)(4)(ii) and § 423.509(a)(4)(ii)).

Right to Request a Hearing

Humana may request a hearing to appeal CMS’s determination in accordance with the procedures outlined in 42 C.F.R. Parts 422 and 423, Subpart T. Humana must send a written request for a hearing to the Departmental Appeals Board office listed below within 60 calendar days from receipt of this notice or by February 29, 2016. The request for hearing must identify the specific issues and the findings of fact and conclusions of law with which Humana disagrees. Humana must also specify the basis for each contention that the finding or conclusion of law is incorrect. The request should be sent to:

Civil Remedies Division
Department of Health and Human Services
Departmental Appeals Board
Medicare Appeals Council, MS 6132
330 Independence Ave., S.W.
Cohen Building Room G-644
Washington, D.C. 20201

A copy of the hearing request should also be sent to CMS at the following address:

Vikki Ahern
Acting Director, Division of Compliance Enforcement
Centers for Medicare & Medicaid Services
If Humana does not request an appeal in the manner and timeframe described above, the initial determination by CMS to impose a CMP will become final and due on March 1, 2016. Humana may choose to have the penalty deducted from its monthly payment, transfer the funds electronically, or mail a check to CMS. To notify CMS of your intent to make payment and for instructions on how to make payment, please call or email the enforcement contact provided in the email notification.

Please note that further failures by Humana may result in additional applicable remedies available under law, up to and including contract termination, the imposition of intermediate sanctions, penalties, or other enforcement actions as described in 42 C.F.R. Parts 422 and 423, Subparts K and O.

If Humana has any questions about this notice, please call or email the enforcement contact provided in the email notification.

Sincerely,

/s/

Gerard J. Mulcahy
Director
Medicare Parts C and D Oversight and Enforcement Group

cc: Vikki Ahern, CMS/CM/MOEG/DCE
    Kevin Stansbury, CMS/CM/MOEG/DCE
    Judith Flynn, CMS/CMHPO/Region VII
    Sue Lovett, CMS/CMHPO/Region VII
    Uvonda Meinholdt, CMS/CMHPO/Region VII